Standard BioTools Inc. (NASDAQ:LAB) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its position in shares of Standard BioTools Inc. (NASDAQ:LAB) by 0.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,975,221 shares of the company’s stock after acquiring an additional 25,504 shares during the period. Geode Capital Management LLC owned approximately 1.87% of Standard BioTools worth $12,209,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Takeda Pharmaceutical Co. Ltd. bought a new stake in shares of Standard BioTools in the 4th quarter worth approximately $29,000. Cibc World Markets Corp bought a new position in shares of Standard BioTools in the fourth quarter valued at $48,000. Simon Quick Advisors LLC acquired a new stake in shares of Standard BioTools during the 4th quarter valued at $54,000. KLP Kapitalforvaltning AS acquired a new position in shares of Standard BioTools in the 4th quarter worth $70,000. Finally, HighTower Advisors LLC raised its position in shares of Standard BioTools by 13.0% during the fourth quarter. HighTower Advisors LLC now owns 92,791 shares of the company’s stock worth $162,000 after purchasing an additional 10,690 shares during the period. 53.74% of the stock is currently owned by institutional investors.

Standard BioTools Stock Performance

NASDAQ LAB opened at $1.19 on Tuesday. The firm’s 50 day moving average price is $1.17 and its two-hundred day moving average price is $1.58. The stock has a market cap of $450.99 million, a price-to-earnings ratio of -1.68 and a beta of 1.54. Standard BioTools Inc. has a twelve month low of $0.97 and a twelve month high of $2.74.

Insider Activity at Standard BioTools

In related news, Director Casdin Partners Master Fund, L bought 4,820,959 shares of the firm’s stock in a transaction on Friday, February 28th. The stock was bought at an average price of $1.06 per share, with a total value of $5,110,216.54. Following the purchase, the director now directly owns 58,846,780 shares of the company’s stock, valued at approximately $62,377,586.80. This represents a 8.92 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 53.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Separately, KeyCorp cut Standard BioTools from an “overweight” rating to a “sector weight” rating in a research note on Thursday, February 27th.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.